Loading patent…
AssigneesProvectus Pharmatech, Inc., University of Tennessee Research Foundation
InventorsMichio Kurosu, Dominic Rodrigues, Edward V. Pershing, Bruce Horowitz, John Lacey, III, Eric A. Wachter, Edward P. Gamson
Estimating the term…
The present invention contemplates a topical ophthalmic system for treating a Gram-positive bacterially-infected mammalian eye. The system comprises an ophthalmic composition containing a halogenated fluorescein or a pharmaceutically acceptable salt or ester thereof dissolved or dispersed in an aqueous ophthalmic carrier and present in an anti-bacterial keratitis-treating effective concentration of about 0.2 μg/mL to about 50 μg/mL. The ophthalmic composition has a pH value of about 6.5 to about 7.6, a viscosity of about 10 to about 300 cps and an osmolality of about 270 mOsm/kg to about 340 mOsm/kg. The ophthalmic composition is present in a vessel opaque to actinic light. Also contemplated is a method of treating a mammal having a Gram-positive bacterial infection of an eye by administering the ophthalmic composition to the infected eye and maintaining the treated eye in the substantial absence of actinic light for about 3 hours to about 12 hours.
A method of treating a mammalian subject having a Gram-positive bacterially-infected eye that exhibits keratitis consisting of the steps of treating said Gram-positive bacterially-infected eye by administering to that microbially-infected eye a keratitis-treating effective amount of an ophthalmic composition containing a halogenated fluorescein or pharmaceutically acceptable salt, amide or ester thereof dissolved or dispersed in an aqueous ophthalmic carrier and present in a bacterial keratitis-treating effective concentration of about 0.2 μg/mL to about 50 μg/mL in the composition, said ophthalmic composition having a pH value of about 6.5 to about 7.6, a viscosity of about 10 to about 300 cps and an osmolality of about 270 mOsm/kg to about 340 mOsm/kg, and maintaining said treated eye in the substantial absence of actinic light for a time period of about 3 to about 12 hours so that said treatment is carried out in the substantial absence of actinic light.
Dependencies are inferred from the claim text.